Compare SOBR & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | BBLG |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Newspapers/Magazines | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.6M |
| IPO Year | 2008 | N/A |
| Metric | SOBR | BBLG |
|---|---|---|
| Price | $0.90 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 191.0K | 37.2K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $437,421.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.62 | N/A |
| 52 Week Low | $0.48 | $1.05 |
| 52 Week High | $5.27 | $4.13 |
| Indicator | SOBR | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 64.18 |
| Support Level | $0.69 | $1.24 |
| Resistance Level | $1.03 | $1.88 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 31.30 | 75.76 |
Sobr Safe Inc is a hardware and software company. The Company integrates proprietary software, SOBRsafeTM, with its patented touch-based personal alcohol awareness tracking products, SOBRcheckTM and SOBRsure, enabling non-invasive personal alcohol awareness tracking, biometric identity verification, and qualified, real-time cloud-based, informational alerts and reporting. It operates as a single segment designed to enable customers to purchase products directly through channel partners, sales agents or through its enterprise and consumer digital channels. Currently its principal markets are located in North America.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.